3Fellows L, Ahmad F, Castle D J, et al. Investigation of target plas- maconcentration-effect relationships for olanzapine in schizophre- nia. Therapeutic Drug,2003,25 ( 6 ) :682-689.
4Perry PJ, Land BC, Sanger T, et al. Olanzapine plasma concentra- tions and clinical response:acute phase results of the North Ameri- can olanzapine trial. J Clin Psychopharmacol,2001 ;21 ( 1 ) :14-20.
3Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first episode psychosis. Am J Psychiatry,1999,156:79-87.
4Tollefson GD, Sanger riM. Negative symptoms: a path analytic approach to a double-build, placebo and haloperidol controlled clinical trial with olanzapine, Am J psychiatry, 1997,154:466-474.
5Olesen OV, linet K. Determination of olanzapine in serum by HPLC using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J Chromatogr B Biomed Sci Appl,1998,714:309-315.
6Midha KIC Intersubjeet variation in the pharmacokinetics of haloperidol and reduced holoperidol. J Clin Psychoparmacol, 1999,9:98-99.
7Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely schizophrenic patients. J Chin Psychopharmacol, 1997,17:472-477.
8Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J clin Psychiatry, 1997,58 Suppl 10:13-17.
9Bergmann N,Frich A,Parzer P,et al.Olanzapine plasma concentration,average daily dose,and interaction with co-medication in schizophrenic patients[J].Pharmacopsychiatry,2004,37 (2):63.
10Olesen OV,Linnet K.Determination of olanzapine in serum by HPLC using ultraviolet detection considering the easy oxidability of the compound and the pesence of other psychotropic drugs[J].J Chromatogr B,1998,714:309.
8Harvey PD, Green MF, Bowie C, et al. The dimensions of clinical and cognitive change in schizophrenia:evidence for independence of improvements. Psychopharmacology ( Berl ), 2006, 187 ( 3 ) : 356-363.
9Green MF, Nuechtedein KH, Gold JM,et al. Approaching a con- sensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry,2004,56 ( 5 ) :301-307.
10Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in sehizophrenia:are we measuring the "fight stuff". Sehizophr Bu11,2000,26 ( 1 ) : 119-136.
